The President of the Moderna pharmaceutical company Stephen Hoge said in an interview on Thursday that the research indicates that SARS CoV2 virus is likely to stay long-term and there will be more rounds of the outbreak, potentially even annually. In light of continued infection and emerging variants, Moderna’s leadership sees using “multivalent boosters” as a response. The company is in the last stages of testing before filing for regulatory approval of a booster dose. Hoge noted that booster shots will likely be necessary this fall. Moderna’s booster strategy is pursuing three options: a third dose of original vaccine, a variant-specific shot and a combination of both. The company is also looking to develop a jab against all variants of the COVID-19 virus.